Loading
When a tumour evolves resistance to one drug, it sometimes becomes weaker against another. Map these trade-offs systematically so doctors can pick the next drug to exploit them.
Collateral sensitivity is well characterised in antibiotics and shown in a few oncology examples (MEK-inhibitor resistance sensitising to certain agents, ABL inhibitor rotation in CML). A systematic programme would evolve resistance to each approved targeted agent in dozens of models, screen the resistant derivatives against the full pharmacopoeia, and publish a public sensitivity map to inform sequencing trials.
Shares CRISPR functional genomics, Functional (ex vivo) drug testing, Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares CRISPR functional genomics, Tumour heterogeneity and clonal evolution, Drug resistance (primary and acquired).
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
Shares Tumour heterogeneity and clonal evolution, Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Tumour heterogeneity and clonal evolution, Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Too many combinations to test, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy.
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.